Biogaia AB
OTC:BGAIF
Intrinsic Value
BioGaia AB engages in the development, marketing, and sale of probiotic products. [ Read More ]
The intrinsic value of one BGAIF stock under the Base Case scenario is 2.4 USD. Compared to the current market price of 10.04 USD, Biogaia AB is Overvalued by 76%.
Valuation Backtest
Biogaia AB
Run backtest to discover the historical profit from buying and selling BGAIF stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Biogaia AB
Current Assets | 1.9B |
Cash & Short-Term Investments | 1.5B |
Other Current Assets | 330.2m |
Non-Current Assets | 458.8m |
Long-Term Investments | 28.1m |
PP&E | 213.3m |
Intangibles | 211.4m |
Other Non-Current Assets | 6m |
Current Liabilities | 195.7m |
Other Current Liabilities | 195.7m |
Non-Current Liabilities | 107.1m |
Other Non-Current Liabilities | 107.1m |
Earnings Waterfall
Biogaia AB
Revenue
|
1.3B
SEK
|
Cost of Revenue
|
-346.3m
SEK
|
Gross Profit
|
950.2m
SEK
|
Operating Expenses
|
-507.1m
SEK
|
Operating Income
|
443.1m
SEK
|
Other Expenses
|
-77.8m
SEK
|
Net Income
|
365.4m
SEK
|
Free Cash Flow Analysis
Biogaia AB
BGAIF Profitability Score
Profitability Due Diligence
Biogaia AB's profitability score is 76/100. The higher the profitability score, the more profitable the company is.
Score
Biogaia AB's profitability score is 76/100. The higher the profitability score, the more profitable the company is.
BGAIF Solvency Score
Solvency Due Diligence
Biogaia AB's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Biogaia AB's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BGAIF Price Targets Summary
Biogaia AB
According to Wall Street analysts, the average 1-year price target for BGAIF is 13.59 USD .
Shareholder Return
BIOG B Price
Biogaia AB
Average Annual Return | 1.36% |
Standard Deviation of Annual Returns | 20.27% |
Max Drawdown | -99% |
Market Capitalization | 11.5B SEK |
Shares Outstanding | 100 982 310 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
BioGaia AB engages in the development, marketing, and sale of probiotic products. The company is headquartered in Stockholm, Stockholm. The firm develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The firm operates worldwide.
Contact
IPO
Employees
Officers
The intrinsic value of one BGAIF stock under the Base Case scenario is 2.4 USD.
Compared to the current market price of 10.04 USD, Biogaia AB is Overvalued by 76%.